ArticleBMC cardiovascular disorders2026
Higher fatty liver index is associated with increased risk of incident atrial fibrillation in adults with diabetes: a prospective UK biobank study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWhether hepatic steatosis, as indexed by the fatty liver index (FLI), is associated with incident atrial fibrillation (AF) among adults with diabetes beyond shared cardiometabolic risk factors remains uncertain.
objectiveTo investigate the association between fatty liver index and incident atrial fibrillation in adults with diabetes.
methodsWe analyzed 29,341 UK Biobank participants with baseline diabetes and no history of atrial fibrillation or atrial flutter, and no prior cardiovascular disease. FLI was evaluated both categorically (< 30, 30–59, 60–89, ≥ 90) and continuously using restricted cubic splines. Incident AF was identified through linked health records, with death treated as a competing risk. Cox models were sequentially adjusted for demographics, lifestyle, socioeconomic status, and metabolic factors; Fine–Gray models were also applied. Sensitivity analyses included 1:10 propensity score matching (FLI ≥ 60 vs. < 60). Among participants with FLI ≥ 30, AF risk was further stratified by the number of metabolic abnormalities (hypertension, obesity, dyslipidemia), grouped as 0, 1, 2, or ≥ 3.
resultsOver a median follow-up of 14.1 years (13.4–14.7), 2,890 incident AF events occurred. AF incidence rose across FLI categories, from 4.88 (95% CI: 4.21–5.63) to 9.92 (95% CI: 9.38–10.48) per 1,000 person-years comparing FLI < 30 with FLI ≥ 90, an absolute difference of 5.04 (95% CI: 4.15–5.92). In fully adjusted Cox models, FLI ≥ 90 was associated with a higher AF risk (HR 1.64, 95% CI: 1.40–1.92; p < 0.001), with attenuated estimates for intermediate FLI groups and a significant trend across categories (p < 0.001). Among individuals with FLI ≥ 30, AF risk increased stepwise with the number of metabolic abnormalities. Spline analyses showed a nonlinear association (p < 0.001), with AF risk increasing more noticeably at higher FLI values, particularly in the very high range.
conclusionsAmong adults with diabetes, higher FLI was associated with a greater risk of incident AF after adjustment for measured demographic, lifestyle, and cardiometabolic factors, with the strongest association observed at very high FLI levels. These findings suggest that FLI may serve as an accessible marker for risk stratification in this high-risk population; however, residual confounding cannot be excluded and clinical utility for decision-making requires further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.